歡迎來到北京博奧森生物技術有限公司網站！歡迎來到北京博奧森生物技術有限公司網站！
18611424007
截止目前，引用Bioss產品發(fā)表的文獻共35263篇，總影響因子175,814.81分，發(fā)表在Nature, Science, Cell以及Immunity等頂級期刊的文獻共126篇，合作單位覆蓋了清華、北大、復旦、華盛頓大學、麻省理工學院、東京大學以及紐約大學等上百所國際研究機構。
我們每月收集引用Bioss產品發(fā)表的文獻。若您在當月已發(fā)表SCI文章，但未被我公司收集，請致電Bioss，我們將贈予現(xiàn)金鼓勵，金額標準請參考“發(fā)文章 領獎金"活動頁面。
本文主要分享引用Bioss產品發(fā)表文章至Signal Transduction and Targeted Therapy, Journal of Thoracic Oncology, Bioactive Materials, Advanced Functional Materials等期刊的10篇IF≥19的文獻摘要，讓我們一起欣賞吧。
Signal Transduction and
Targeted Therapy [IF=52.7]
文獻引用產品：
bsm-60738R | Ki67 Recombinant Rabbit mAb | IHC
bs-0646R | CD34 Rabbit pAb | IHC
作者單位：南方醫(yī)科大學
摘要：Nanoparticle-based drug delivery system remains a significant challenge in the current treatment of solid tumors, primarily due to their limited penetration capabilities. Herein, we successfully engineer photodynamic gel-bombs (DCM@OPR) capable of penetrating deeply into tumor tissues utilizing the photodynamic-triggered explosive energy and receptor-mediated transcytosis, significantly enhancing the therapeutic efficacy of breast cancer. The photodynamic gel-bombs were fabricated by loading powerful components of chlorin e6 and MnO2 nanoparticles, as well as Doxorubicin, into a crosslinked Ca2+-gel. Upon exposure to laser irradiation, the obtained photodynamic gel-bombs are capable of generating explosive energy, resulting in their fragmentation into numerous nanofragments. The photodynamic-triggered explosive energy subsequently drives these nanofragments to deeply penetrate into tumor tissues through gap leakage among tumor cells. In addition, the photodynamic-triggered explosive energy also promotes the escape of those therapeutic components (including chlorin e6, MnO2 nanoparticles, and doxorubicin) and nanofragments from lysosomes. In the subsequent stages, these nanofragments also exhibit excellent transcytosis capacity, facilitating deep penetration into tumor tissues. As expected, the enhanced penetration and accumulation of therapeutic components into tumor tissues can be achieved, significantly enhancing the anti-proliferation capacity against breast cancer.
Journal of Thoracic
Oncology [IF=20.8]
文獻引用產品：
bs-1351R | Granzyme B Rabbit pAb | mIF
bs-20765R | CCL5/RANTES Rabbit pAb | mIF
作者單位：同濟大學醫(yī)學院
摘要：Introduction：Accumulation of regulatory T (Treg) cells, an immunosuppressive population, limits the efficacy of immunotherapy in NSCLC. C-C motif chemokine receptor 8 (CCR8) is selectively expressed in tumor-infiltrating Treg cells and is, therefore, considered an ideal target.
Methods：The efficacy and safety of anti-CCR8 monotherapy and its combination with programmed cell death protein-1 (PD1) inhibitor were evaluated in four NSCLC-bearing mice models. To track the dynamic changes in tumor microenvironment, we performed the single-cell RNA sequencing, the single-cell T-cell receptor sequencing analysis, the flow cytometry, the multi-color immunofluorescence, and the Luminex assay on tumors after three, seven, 14, and 21 days of different treatment regimens. Then, in vitro and in vivo experiments were applied to validate our findings and explore molecular mechanisms of the synergistic effects.
Results：Across four NSCLC-bearing mice models, the combination of CCR8 antibody and PD1 inhibitor significantly reduced tumor growth (p < 0.05) without obvious mouse body weight drops and systemic cytokine storm. The anti-CCR8 therapy synergizes with PD1 blockade by remodeling the tumor microenvironment and disrupting CCR8+Treg–C-C motif chemokine ligand 5 (CCL5)+ dendritic cells (DC) interaction. Mechanistically, therapeutic depletion of CCR8+Treg cells combined with PD1 inhibitor extremely increased interleukin-12 secretion by the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway activation on CCL5+ DCs, thereby promoting cytotoxic activity of CD8+ T cells. The therapeutic potential of the CCR8 antibody LM-108 in combination with immunotherapy was observed in clinical patients with advanced NSCLC.
Conclusion：Overall, CCR8 expression on tumor-infiltrating Treg cells is correlated with immunosuppressive function on DCs and CD8+ T cells, thus impeding antitumor immunity.
Bioactive Materials [IF=20.3]
文獻引用產品：
作者單位：中山大學附屬第三醫(yī)院
摘要：Acute liver failure (ALF) is a highly lethal condition characterized by massive tissue necrosis, excessive oxidative stress, and serious inflammatory storms, necessitating prompt medical intervention. Although hepatocyte-like cells (HLCs) derived from mesenchymal stromal/stem cells (MSCs) offer a promising alternative cell source for hepatocyte therapy, their low in-vivo integration and differentiation efficiency may compromise the eventual therapeutic efficacy. To this end, MSCs are bioengineered into multicellular spheroids in the present study. The proteomic analyses and experimental results reveal that extracellular vesicles (EVs) derived from these MSC spheroids (SpEV) contain abundant highly expressed bioactive proteins and can be efficiently endocytosed by recipient cells, resulting in enhanced pro-angiogenic and antioxidative effects. In addition, MSC spheroids exhibit superior hepatic cell differentiation compared to an equivalent number of dissociated single MSCs, particularly when being co-cultured with hexagonally patterned endothelial cells in a liver lobule-like arrangement. Following orthotopic implantation in the mouse model, the enhanced paracrine effects of SpEV, combined with an immunoregulatory decellularized extracellular matrix hydrogel carrier and functional artificial liver lobules (ALL), synergically contribute to the effective amelioration of ALF, highlighting the substantial potential for clinical translation.
Advanced Functional
Materials [IF=19]
文獻引用產品：
摘要：Transarterial chemoembolization (TACE) is considered the main treatment for intermediate and advanced liver cancer. Nevertheless, TACE may aggravate liver fibrosis in these patients, which could affect the therapeutic effect after TACE. Pirfenidone (PFD) exhibits significant antifibrotic effects in the liver, primarily via inhibition of hepatic stellate cells (HSCs) activation. However, owing to the high dose required for effective treatment, oral administration of PFD is associated with several side effects. This study introduces an oral folic acid (FA)-modified protein-polysaccharide PFD nanoemulsion designed to treat post-TACE liver fibrosis via liver targeting. This novel PFD oral nanoemulsion withstands gastrointestinal digestion and ensures the gastrointestinal stability of PFD. Furthermore, this nanoemulsion improves the intestinal permeability and antifibrotic efficacy of PFD at a lower dose via folate receptors expressed on both intestinal epithelial cells and activated HSCs. In conclusion, this FA-modified protein-polysaccharide nanoemulsion presents a promising approach for oral PFD delivery to effectively ameliorate fibrosis after TACE for liver cancer.
Advanced Functional
Materials [IF=19]
文獻引用產品：
Advanced Functional
Materials [IF=19]
文獻引用產品：
Advanced Functional
Materials [IF=19]
文獻引用產品：
bs-2696R | S100-A8 / MRP8 Rabbit pAb | IF
作者單位：四川大學
摘要：Inhalation offers a non-invasive method to administer drugs to lungs, but achieving selective delivery to pulmonary lesions while sparing normal lung tissues remains challenging. Here, the development of an inhalable chemotactic liposome designed for targeted modulation of pulmonary pre-metastatic niche (PMN) is reported. The inhaled liposome can migrate along chemokine gradients, preferentially accumulating in chemokine-secreting PMNs within the lung. Upon localized drug release, the liposome mitigates fibrosis, and disrupts PMN evolution, thereby attenuating the pro-metastatic role of PMN as a hospitable “soil" for residual tumor cell “seeding" post-surgery. This approach further complements a sprayable hydrogel developed for immediate post-surgical application within the tumor resection cavity. While this hydrogel alone reduces the metastatic potential of postoperative tumor residues, it proves insufficient in halting the spread to lungs. However, the integration of the inhalable liposome and sprayable hydrogel into a dual-pronged strategy presents a patient-friendly method that simultaneously targets both the pro-metastatic PMN “soil" and metastatic tumor “seeds", resulting in significant inhibition of postoperative lung metastasis.
Advanced Functional
Materials [IF=19]
文獻引用產品：
作者單位：廣西醫(yī)科大學附屬腫瘤醫(yī)院
摘要：Ferroptosis is a newly identified type of regulated cell death characterized by iron-dependent lipid peroxidation. Among the main ferroptosis-suppressing systems, the dihydroorotate dehydrogenase (DHODH)- ubiquinone axis is closely related to mitochondria and energy metabolism, implying that the axis protects cells from oxidative stress damage via the maintenance of redox homeostasis. However, ferroptosis initiation requires a suitable oxidative environment and a breakthrough in redox homeostatic limitations by ferroptosis-suppressing systems. Hence, the nanoparticles are rationally engineered to achieve efficient ferroptosis induction by releasing dual-release free iron and disrupting ferroptosis-suppressing systems. Atovaquone (ATO)-loaded hollow mesoporous etching zeolitic imidazolate framework-67 double-coated iron oxide/calcium phosphate (Fe3O4/CaP) is conjugated with polyethylene glycol. The external double-coated Fe3O4/CaP structure enhances the efficiency of multiple reactive oxygen species (ROS) generation promoting oxidative stress. Still, it achieves free iron dual-release to increase the content of unstable iron pools for igniting the ROS storm and lipid peroxidation spark. The release of ATO not only affects the energy metabolism of the mitochondrial respiratory chain by binding to complex III but also downregulates DHODH to restrict the ubiquinol system to disrupt the ferroptosis-suppressing systems. Therefore, the design of this composite nanomedicine provides an approach for inducing ferroptosis and a theoretical basis for clinical ferroptosis anti-tumor trials.
Advanced Functional
Materials [IF=19]
文獻引用產品：
作者單位：溫州醫(yī)科大學
摘要：Surface-enhanced Raman scattering (SERS) substrates based on 2D semimetallic materials have emerged as novel detecting platforms for detecting at the single-molecule level due to the high charge transfer efficiency between the layered materials and analytes. However, current methods such as chemical vapor deposition (CVD) or liquid-phase exfoliation face significant challenges in simultaneously achieving high yield and low defect density in preparing layered materials, which often leads to compromises in SERS efficiency or sensitivity, thereby limiting large-scale applications. Herein, an improved electrochemical cathodic exfoliation (ECE) protocol, developed through recent advancements, is employed to produce highly uniform and solution-processable TiSe2, NbSe2, and TaSe2 monolayers with over 95% yield in 120 min. The SERS sensitivity (10?16 M for Rhodamine 6G) of 2D materials from ECE rivals that of CVD-prepared monolayers due to their low defect density. Using NbSe2 as the SERS substrate, matrix metalloproteinase-9 in tear fluid is detected across 0.01 to 100 ng mL?1, outperforming conventional enzyme-linked immunosorbent assay methods that typically detect at 1 ng mL?1. The scalability of the modified ECE process not only facilitates its integration into lateral flow immunoassays but also paves the way for bridging the gap between practical applications and highly sensitive SERS detection using 2D materials.
Advanced Functional
Materials [IF=19]
文獻引用產品：
bsm-60761R | CD206 Recombinant Rabbit mAb | WB, IF
bsm-33033M | GAPDH Mouse mAb, Loading Control | WB
作者單位：河南省中醫(yī)院附屬骨科醫(yī)院
摘要：Insufficient oxygen supply and elevated levels of reactive oxygen species (ROS) in rheumatoid arthritis (RA) joints synergistically exacerbate inflammation and accelerate disease progression. In this study, a hybrid nanoassembly composed of superoxide dismutase (SOD) and catalase (CAT) conjugated within a single poly(ε-caprolactone) (PCL) nanoparticle is developed for RA therapy. The synthesized nanoassembly (PSC) drives a proximity-dependent cascade reaction that efficiently scavenges ROS and generates oxygen, thereby modulating the phenotype of inflammatory macrophages in RA synovium, significantly inhibiting the secretion of pro-inflammatory cytokines, and consequently alleviating inflammation. Furthermore, PSC functions as a versatile drug delivery platform for hydrophobic small-molecule drugs. Iguratimod (IGU), an anti-rheumatic drug with bone-protective properties, is incorporated into the PSC (PSC@IGU), which is then loaded into dissolvable microneedles (MNs) to enhance drug delivery efficiency. Finally, PSC@IGU MNs demonstrate significant therapeutic effects in RA mouse models by effectively improving joint hypoxia, alleviating synovial inflammation, and preventing bone erosion. This study highlights the potential of PSC@IGU-loaded MNs for the treatment of RA, indicating their promising ability to bridge basic research with clinical translation.
網站首頁
